All babies born in 2024 eligible to receive RSV shots

All infants up to 12 months old and children up to 24 months at high risk of severe illness from Respiratory Syncytial Virus (RSV) are eligible for immunization before and during the active RSV season.

Monoclonal antibody immunization is currently funded for RSV prevention in infants and children who are residents of Ontario and meet any of the following criteria:

• RSV born in 2024 prior to the RSV season (the National Advisory Committee on Immunization specifically recommends that infants less than 8 months of age or less be immunized)
• born during the 2024–25 RSV season
• Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season, following discussion with a health care provider, including:
  • chronic lung disease (CLD), including bronchopulmonary dysplasia/chronic lung disease
  • hemodynamically significant congenital heart disease (CHD)
  • severe immunodeficiency
  • Down Syndrome/Trisomy 21
  • cystic fibrosis with respiratory involvement and/or growth delay
  • neuromuscular disease
  • severe congenital airway anomalies impairing the clearing of respiratory secretions

If you are unsure whether your child is eligible, contact a healthcare provider to discuss.

The RSV immunization product, Beyfortus®, for infants, will be available through:

• hospitals
• primary care offices

For more information, visit Respiratory Syncytial Virus | ontario.ca